Cited by

• Advances in sickle cell therapies in the hydroxyurea era.

  Field JJ, Nathan DG. Field JJ, et al. Mol Med. 2014 Dec 16;20 Suppl 1(Suppl 1):S37-42. doi: 10.2119/molmed.2014.00187. Mol Med. 2014. PMID: 25549232 Free PMC article. Review.
• Emerging point-of-care technologies for sickle cell disease screening and monitoring.

  Alapan Y, Fraiwan A, Kucukal E, Hasan MN, Ung R, Kim M, Odame I, Little JA, Gurkan UA. Alapan Y, et al. Expert Rev Med Devices. 2016 Dec;13(12):1073-1093. doi: 10.1080/17434440.2016.1254038. Epub 2016 Nov 22. Expert Rev Med Devices. 2016. PMID: 27785945 Free PMC article. Review.
• The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.

  Hebbel RP, Vercellotti GM, Pace BS, Solovey AN, Kollander R, Abanonu CF, Nguyen J, Vineyard JV, Belcher JD, Abdulla F, Osifuye S, Eaton JW, Kelm RJ Jr, Slungaard A. Hebbel RP, et al. Blood. 2010 Mar 25;115(12):2483-90. doi: 10.1182/blood-2009-02-204990. Epub 2010 Jan 6. Blood. 2010. PMID: 20053759 Free PMC article.
• Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule.

  Lombardi E, Matte A, Risitano AM, Ricklin D, Lambris JD, De Zanet D, Jokiranta ST, Martinelli N, Scambi C, Salvagno G, Bisoffi Z, Colato C, Siciliano A, Bortolami O, Mazzuccato M, Zorzi F, De Marco L, De Franceschi L. Lombardi E, et al. Haematologica. 2019 May;104(5):919-928. doi: 10.3324/haematol.2018.198622. Epub 2019 Jan 10. Haematologica. 2019. PMID: 30630982 Free PMC article.
• P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab.

  Karki NR, Kutlar A. Karki NR, et al. J Pain Res. 2021 Mar 30;14:849-856. doi: 10.2147/JPR.S278285. eCollection 2021. J Pain Res. 2021. PMID: 33833562 Free PMC article. Review.